ERBB2 and breast cancer: More recently, the Martin-Castillo study revealed the new concept that the differential enrichment of trastuzumab-responsive ALDH+ CSCs versus trastuzumab-refractory CD44high/CD24low cells could explain both the clinical behavior and the efficacy of primary trastuzumab in each distinct intrinsic molecular subtype of HER2+ BC [29].